RBC Capital Initiates Coverage of Solid Biosciences at Outperform
Fintel reports that on September 16, 2026, RBC Capital initiated coverage of Solid Biosciences (NASDAQGS:SLDB) with a Outperform recommendation. This initiation of coverage by RBC Capital occurred on September 16, 2026, following a period of market activity where the stock closed at $8.37 on September 15, 2026.
Prior to this rating action, the stock experienced a price change of -15.71% over one week, moving from a baseline close of $9.93 on September 8, 2026, to its pre-action close of $8.37 on September 15, 2026. Over a one-month period, the stock's price changed by -9.02% from a baseline close of $9.20 on August 14, 2026.
Separately from RBC Capital's individual rating, the current consensus target mean for the stock was recorded at $19.38 as of September 15, 2026, which represents an implied change of +131.54% from the pre-action close. The current consensus target median on that same date was $18.87. This mean target is unchanged from the prior consensus target mean of $19.38 recorded on August 28, 2026, representing a consensus target revision of 0.00%. In terms of aggregate analyst recommendations, the current recommendation period as of September 1, 2026, shows a total of 19 recommendations, consisting of 8 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell ratings. This results in a positive recommendation percentage of 94.7%, a hold percentage of 5.3%, and a negative percentage of 0.0%. These figures are identical to the prior recommendation period as of August 1, 2026, which also had a total of 19 recommendations with the same distribution.
Other recent analyst activities include HC Wainwright & Co. reiterating its Buy rating with a to-rating of Buy on September 14, 2026. Prior to that, Cantor Fitzgerald maintained its Overweight rating with a to-rating of Overweight on August 27, 2026, and Truist Securities maintained its Buy rating with a to-rating of Buy on August 21, 2026.
Solid Biosciences last reported earnings on August 6, 2026. For the quarter, the company reported an actual EPS of -0.38, compared to an estimated EPS of -0.4776. Both actual and estimated revenues were reported at $0.00. On the same day as the earnings release, August 6, 2026, the company filed a Form 8-K current report with the United States Securities and Exchange Commission. According to the filing, Solid Biosciences Inc. is a Delaware-incorporated entity with its principal executive offices located at 500 Rutherford Avenue, Charlestown, Massachusetts 02129, and can be reached at the telephone number (617) 337-4680.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 16, 2026 | RBC Capital | Outperform | initiated coverage | |
| September 14, 2026 | HC Wainwright & Co. | Buy | Buy | reiterated |
| August 27, 2026 | Cantor Fitzgerald | Overweight | Overweight | maintained |
| August 21, 2026 | Truist Securities | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.